CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 21 enrolled / 21 target
Drug / intervention
Belantamab mafodotin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06956170
NCT06956170Phase 3ActiveUpdate Overdue (0.4/mo)Completion was 25mo ago
CompareCT.gov

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)

GlaxoSmithKline·interventional·Posted May 4, 2025·Updated Jun 12, 2026

In Brief

A Phase 3 clinical trial evaluating Belantamab mafodotin, Pomalidomide, and 2 other interventions for Multiple Myeloma. Active but no longer recruiting, targeting 21 participants across 13 sites.

Signals

Enrollment appears stalled

Detailed Summary

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesJapan
Collaborators--

Timeline

Phase 3Active
20222023202420252026202720282029
First PostedMay 4, 2025
Enrollment StartFeb 10, 2022
Primary CompletionMay 27, 2024
Study CompletionJun 25, 2029
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 1.2 years ago

Arms & Interventions

Belantamab mafodotin plus Pomalidomide and Dexamethasoneexperimental

Drug: Belantamab mafodotinDrug: PomalidomideDrug: Dexamethasone
Bortezomib plus Pomalidomide and Dexamethasoneactive_comparator

Drug: PomalidomideDrug: DexamethasoneDrug: Bortezomib

Interventions

Belantamab mafodotindrug

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.

Pomalidomidedrug

Immunomodulatory drug (IMiD) will be administered.

Dexamethasonedrug

Synthetic glucocorticoid with anti-tumor activity will be administered.

Bortezomibdrug

Proteasome Inhibitor will be administered.